GBP104.02
2.79% today
London, Jul 01, 05:41 pm CET
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

AstraZeneca Target price 2025 - Analyst rating & recommendation

AstraZeneca Classifications & Recommendation:

Buy
83%
Hold
17%

AstraZeneca Price Target

Target Price GBP142.80
Price GBP104.02
Potential 37.28%
Number of Estimates 29
29 Analysts have issued a price target AstraZeneca 2026 . The average AstraZeneca target price is GBP142.80. This is 37.28% higher than the current stock price. The highest price target is GBP182.70 75.64% , the lowest is GBP68.65 34.01% .
A rating was issued by 35 analysts: 29 Analysts recommend AstraZeneca to buy, 6 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2026 of 37.28% . Most analysts recommend the AstraZeneca stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032


Dec '24 2025
Estimates
Revenue Billion GBP 39.38 43.14
18.03% 9.56%
EBITDA Margin 30.60% 36.36%
9.68% 18.81%
Net Margin 13.01% 24.17%
0.09% 85.78%

31 Analysts have issued a sales forecast AstraZeneca 2025 . The average AstraZeneca sales estimate is GBP43.1b . This is 7.75% higher than the revenue of the last 12 months(TTM). The highest sales forecast is GBP45.5b 13.63% , the lowest is GBP38.4b 4.11% .

This results in the following potential growth metrics:

Revenue Estimates

2024 GBP39.4b 18.03%
2025 GBP43.1b 9.56%
2026 GBP45.8b 6.09%
2027 GBP48.4b 5.77%
2028 GBP50.6b 4.55%
2029 GBP54.1b 6.97%
2030 GBP58.8b 8.61%
2031 GBP61.4b 4.45%
2032 GBP61.7b 0.42%

26 Analysts have issued an AstraZeneca EBITDA forecast 2025. The average AstraZeneca EBITDA estimate is GBP15.7b . This is 25.93% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is GBP19.7b 57.84% , the lowest is GBP11.8b 5.31% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 GBP12.1b 29.46%
2025 GBP15.7b 30.18%
2026 GBP17.3b 10.39%
2027 GBP18.8b 8.79%
2028 GBP19.9b 5.57%
2029 GBP22.7b 13.91%
2030 GBP26.7b 17.78%
2031 GBP28.7b 7.70%
2032 GBP29.3b 1.90%

EBITDA Margin

2024 30.60% 9.68%
2025 36.36% 18.81%
2026 37.84% 4.07%
2027 38.92% 2.85%
2028 39.30% 0.98%
2029 41.85% 6.49%
2030 45.38% 8.43%
2031 46.80% 3.13%
2032 47.49% 1.47%

28 AstraZeneca Analysts have issued a net profit forecast 2025. The average AstraZeneca net profit estimate is GBP10.4b . This is 84.24% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is GBP11.7b 106.55% , the lowest is GBP8.4b 49.26% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 GBP5.1b 18.14%
2025 GBP10.4b 103.54%
2026 GBP11.8b 13.40%
2027 GBP13.0b 9.77%
2028 GBP14.1b 8.66%
2029 GBP15.9b 12.50%
2030 GBP17.4b 9.81%
2031 GBP16.0b 8.08%
2032 GBP15.0b 6.32%

Net Margin

2024 13.01% 0.09%
2025 24.17% 85.78%
2026 25.84% 6.91%
2027 26.81% 3.75%
2028 27.87% 3.95%
2029 29.31% 5.17%
2030 29.63% 1.09%
2031 26.08% 11.98%
2032 24.33% 6.71%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032


Dec '24 2025
Estimates
Earnings Per Share GBP 3.28 6.73
18.41% 105.18%
P/E 15.05
EV/Sales 4.12

28 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca EPS is GBP6.73 . This is 85.40% higher than earnings per share in the financial year 2024. The highest EPS forecast is GBP7.54 107.71% , the lowest is GBP5.45 50.14% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 GBP3.28 18.41%
2025 GBP6.73 105.18%
2026 GBP7.63 13.37%
2027 GBP8.37 9.70%
2028 GBP9.10 8.72%
2029 GBP10.23 12.42%
2030 GBP11.24 9.87%
2031 GBP10.33 8.10%
2032 GBP9.68 6.29%

P/E ratio

Current 27.88 30.21%
2025 15.05 46.02%
2026 13.27 11.83%
2027 12.09 8.89%
2028 11.13 7.94%
2029 9.89 11.14%
2030 9.01 8.90%
2031 9.80 8.77%
2032 10.46 6.73%

Based on analysts' sales estimates for 2025, the AstraZeneca stock is valued at an EV/Sales of 4.12 and an P/S ratio of 3.67 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.44 26.12%
2025 4.12 7.26%
2026 3.88 5.74%
2027 3.67 5.45%
2028 3.51 4.35%
2029 3.28 6.52%
2030 3.02 7.92%
2031 2.89 4.26%
2032 2.88 0.42%

P/S ratio

Current 3.96 27.33%
2025 3.67 7.19%
2026 3.46 5.74%
2027 3.27 5.45%
2028 3.13 4.35%
2029 2.93 6.52%
2030 2.70 7.92%
2031 2.58 4.26%
2032 2.57 0.41%

Current AstraZeneca Upgrades & Downgrades

Analyst Rating Action Date
Berenberg Bank
Buy
Unchanged May 16 2025
Shore Capital
Buy
Unchanged Apr 29 2025
Berenberg Bank
Buy
Unchanged Mar 26 2025
Shore Capital
Buy
Unchanged Mar 07 2025
JP Morgan Cazenove
Overweight
Unchanged Feb 19 2025
Berenberg Bank
Buy
Unchanged Jan 27 2025
Berenberg Bank
Buy
Unchanged Jan 06 2025
Analyst Rating Date
Unchanged
Berenberg Bank:
Buy
May 16 2025
Unchanged
Shore Capital:
Buy
Apr 29 2025
Unchanged
Berenberg Bank:
Buy
Mar 26 2025
Unchanged
Shore Capital:
Buy
Mar 07 2025
Unchanged
JP Morgan Cazenove:
Overweight
Feb 19 2025
Unchanged
Berenberg Bank:
Buy
Jan 27 2025
Unchanged
Berenberg Bank:
Buy
Jan 06 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today